Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ONCY | US
0.07
5.47%
Healthcare
Biotechnology
30/06/2024
18/10/2024
1.35
1.28
1.35
1.26
Oncolytics Biotech Inc. a development-stage biopharmaceutical company focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep an intravenously delivered immunotherapeutic agent which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and Bavencio a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer. The company was incorporated in 1998 and is headquartered in Calgary Canada.
View LessPositive Momentum
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
201.0%1 month
147.8%3 months
92.5%6 months
69.3%-
-
7.80
-
-
-1.79
-
-
-36.45M
103.76M
103.76M
-
-
-
-
-138.22
5.43
1.41
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.58
Range1M
0.69
Range3M
0.69
Rel. volume
0.85
Price X volume
883.19K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
AVTX | AVTX | Biotechnology | 11.18 | 108.45M | 7.50% | n/a | -80.47% |
CIBUS GLOBAL LTD. | CBUS | Biotechnology | 3.59 | 105.87M | 3.76% | n/a | 81.33% |
Prelude Therapeutics Incorporated | PRLD | Biotechnology | 1.9 | 103.74M | -1.04% | n/a | 9.99% |
Regulus Therapeutics Inc | RGLS | Biotechnology | 1.57 | 102.78M | 3.29% | n/a | 1.45% |
Leap Therapeutics Inc | LPTX | Biotechnology | 2.675 | 102.36M | 14.81% | n/a | 0.73% |
Marinus Pharmaceuticals Inc | MRNS | Biotechnology | 1.85 | 101.91M | 6.32% | n/a | -202.54% |
Coherus BioSciences Inc | CHRS | Biotechnology | 0.8829 | 101.72M | 4.09% | n/a | -354.71% |
INmune Bio Inc | INMB | Biotechnology | 5.11 | 101.34M | 2.20% | n/a | 14.65% |
Genenta Science S.p.A | GNTA | Biotechnology | 5.5 | 100.19M | -4.51% | n/a | 0.00% |
Agenus Inc | AGEN | Biotechnology | 4.62 | 99.66M | 1.09% | n/a | -170.56% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 32.28 | 92.70M | 0.72% | 5.16 | 19.82% |
Saga Communications Inc | SGA | Broadcasting - Radio | 14.48 | 90.67M | 0.91% | 14.48 | 7.10% |
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 12.9 | 19.65M | 2.38% | n/a | 204.46% |
ILAG | ILAG | Building Products & Equipment | 1.03 | 18.60M | 5.10% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.538 | 7.80M | -6.65% | 0.03 | 16.03% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2201 | 3.95M | 4.26% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.06 | 2.76M | 1.92% | n/a | 17.32% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.01 | 897.66K | -12.28% | n/a | -37.05% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 60.38 | 0 | 0.37% | 22.53 | 56.33% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.92 | 0 | -8.84% | n/a | 0.00% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -1.79 | 0.53 | Cheaper |
Ent. to Revenue | - | 3,967.00 | - |
PE Ratio | - | 41.03 | - |
Price to Book | 7.80 | 15.55 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 92.52 | 72.80 | Riskier |
Debt to Equity | - | -1.23 | - |
Debt to Assets | - | 0.25 | - |
Market Cap | 103.76M | 3.66B | Emerging |